In this issue:
Performance status and survival in pembrolizumab-treated advanced NSCLC
Survival with immune checkpoint inhibitors in large-cell neuroendocrine lung tumours
First-line nivolumab, ipilimumab + chemotherapy in NSCLC
5-year outcomes of nivolumab vs. docetaxel in previously treated NSCLC
OS and PD-L1 analysis of extensive-stage SCLC treated with atezolizumab, carboplatin and etoposide
First-line PD-L1 inhibitor ±chemotherapy in advanced NSCLC: immune-related adverse events
Belotecan vs. topotecan monotherapy for sensitive-relapsed SCLC
Ramucirumab + osimertinib in advanced T790M+ EGFR-mutant NSCLC
Oral microbiome variations affect lung cancer risk in never-smokers
Polypharmacy among older advanced lung cancer patients taking EGFR TKIs
Please login below to download this issue (PDF)